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Abstract
Background: Despite the importance of identifying and screening dyslipidemia to prevent coronary artery diseases
CAD(Coronary Artery Disease), little information is available on dyslipidemia in our large area. So the present study
aimed to assess the management status of lipid abnormalities and its association with other CAD risk factors in an
urban population of southeast of Iran.
Methods: This cross-sectional study was a part of the Kerman coronary artery disease risk factor study KERCADRS
(Kerman coronary artery disease risk study) as a population-based, epidemiological research among 5900 individuals
aged 15 to 75 years who were residents of Kerman city, the largest city in Southeast of Iran. Lipid profile was assessed
using enzymatic laboratory methods.
Results: In total, 5558 persons from 5899 participants were assessed in whom 45.1 % were male and 54.9 % female.
Overall 20.9 % had borderline level of cholesterol (200–239 mg/dl) and 8.7 % suffered from hypercholesterolemia
(≥240 mg/dl). The prevalence of undiagnosed dyslipidemia (UDL) was 16.8 % and of diagnosed dyslipidemia (DDL) was
13.2 % that both UDL and DDL were more prevalent in women. Also, UDL was more revealed in third and fourth age
decades. Advanced age, anxiety, obesity (BMI ≥30 Kg/m2), and family history of dyslipidemia predicted dyslipidemia in
study population.
Conclusion: The overall prevalence of UDL was higher than of DDL, and was significantly influenced by advanced age,
anxiety, obesity, and family history of dyslipidemia. The data showed that our health care management system should
improve its strategies to reduce the burden of this important CAD risk factor.
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Background
Over the recent decades, many researches have consist-
ently indicated the increased burden of lipid profile abnor-
malities and its high mortality, morbidity, and medical
costs [1]. Dyslipidemia has been clearly identified as an
important major risk factor for cardiovascular diseases
that are the first cause of death in the developed and de-
veloping countries [2]. The World Health Organization
recently reported that dyslipidemia is significantly associ-
ated with more than half of global cases of ischemic heart
disease [3]. In fact, dyslipidemia is not a single primary
phenomenon, but is a broad term that refers to inappro-
priate diet and lifestyle, as well as some genetic suscepti-
bilities [2]. The literature on the epidemiology and
economics of dyslipidemia is extensive. Quite literally, it
has been demonstrated that a notable number of individ-
uals have total cholesterol levels in excess of 200 mg/dL,
and majority of affected ones have levels greater than
240 mg/dL, which is considered a high level necessitating
treatment [4–6]. Despite the importance of identifying
and screening dyslipidemia in every nation to prevent oc-
currence and progression of cardiovascular diseases, there
are no proper and correct statistics on the incidence of
dyslipidemia and its determinants in majority of nations
[7, 8]. In this regard, awareness of the incidence and con-
trol state of dyslipidemia among high risk groups is now
being increased, leading proper control of this serious risk
factor in some areas [9]. Moreover, the recent report of
the NCEP (National cholestrol education program) sug-
gested that the primary approach to cholesterol lowering
is making lifestyle changes in combination with medica-
tion to control their dyslipidemia [10]. The lack of enough
knowledge to the status of dyslipidemia leads to inappro-
priately programming and treatment approaches.
Unfortunately, there is little information with re-
spect to present status of lipid abnormalities and its
association with other CAD risk factors especially
mental health status among some Iranian population.
This will lead to difficulties in scheduling suitable na-
tional managerial approaches for lipid lowering. Thus,
the present study aimed to assess prevalence of lipid
abnormalities and its associated CAD risk factors, and
the effectiveness of health care system in management
of this CAD risk factor in a relatively large population
that is representative of the urban population in the
Southeast of Iran.
Methods
This cross-sectional study was a part of The Kerman
coronary artery disease risk study (KERCADRS), as a
population-based, epidemiological research among 5900
individuals aged 15 to 75 years. These are residents of
Kerman city that addressed the epidemiological data re-
garding various coronary artery disease risk factors [11].
The study protocol was approved by the Research Ethics
Committee at Kerman University of Medical Sciences,
Kerman, Iran (Permission No. 88/110KA). Baseline demo-
graphic variables were collected either from the medical
records or by interview -completed questionnaires at trial
entry and comprised smoking status and opium use. Daily
physical activities at home and workplace were recorded
using WHO Global Physical Activity Questionnaire
(GPAQ) [12]. To evaluate the intensity of physical activity,
metabolic equivalent (MET) was used. MET is the use of
energy in an adult individual while he/she is sitting. Mod-
erate physical activity is considered as consuming energy
four times, and high physical activity eight times in pro-
portion to sitting. The questionnaire regarding risk pro-
files was completed by trained and certified medical staff.
Beck Anxiety Inventory (BAI) and Beck Depression Inven-
tory (BDI) [13] were of the questionnaires completed by
the interviewers. Participants also underwent a clinical
examination that included measurement of height, weight
according to standardized protocols. Participants were
categorized as overweight and obese if their body mass
index were 25–29.9 and above 30 Kg/m2 respectively.
Furthermore, blood samples were taken after at least
12 h of overnight fasting and FPG (Fasting Plasma Glu-
cose)HbA1C (Hemoglobin A1C), total and HDL(High-
Density Lipoprotein) cholesterol were measured. All
lipid and lipoprotein measurements were made at a
central laboratory. Total cholesterol was measured en-
zymatically with standard methods and triglyceride was
measured via standard spectrophotometric technique.
After the precipitation of low) particle with phospho-
tungstic acid, high-density lipoprotein (HDL) choles-
terol was measured enzymatically in the supernatant by
a modification of the method for total cholesterol.
LDL(Low-Density Llipoprotein) cholesterol was calcu-
lated using the Friedewald formula (LDL = Total chol-
esterol – (HDL + TG (Serum Triglyceride)/5). Lipid
profile was categorized based on the current measure-
ments, history of diagnosis and taking drugs. The cut
off points for these lipid profiles can be seen in Table 1.
More information about the methodology of study has
been published elsewhere [11].
Statistical analysis
Results were presented as mean ± standard deviation
(SD) for quantitative variables and were summarized by
absolute frequencies and percentages for categorical var-
iables. Continuous variables were compared using t test
or ANOVA test or non-parametric Mann–Whitney U or
Kruskal-Wallis tests whenever the data did not have nor-
mal distribution or when the assumption of equal vari-
ances was violated across the groups. Categorical variables
were, on the other hand, compared using chi-square test
or Fisher’s exact test when more than 20 % of cells with
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expected count of less than 5 were observed. Main predic-
tors of dyslipidemia were determined by ANCOVA test
adjusting baseline variables. For age-sex direct standardi-
zations, we used Kerman population reported in census
2006. All prevalence rates were weighted according to the
sampling weight (reciprocal of the probability of selection)
and individual response rate. The statistical software SPSS
version 20.0 for windows (SPSS Inc., Chicago, IL) was
used for statistical analysis. P values of 0.05 or less were
considered statistically significant.
Results
Total population were 5899 persons from that, data of
5558 individuals were analyzed because their laboratory
lipid measurement data was complete. From this popula-
tion 45.1 % were male and 54.9 % were female, 20.9 %
had borderline and 8.7 % had increased level of choles-
terol (Table 2). Borderline level of serum triglyceride was
revealed in 13.8 % and high serum level in 14.1 %. In this
regard, abnormal increased level of LDL-C and low level
of HDL-C were reported in 10.4 and 77.4 % respectively.
High cholesterol level was more specified to women
than in men, whereas increased level of serum triglycer-
ide was more observed in men. Moreover, women had
higher level of LDL-C and lower level of HDL-C com-
pared with men. There was an overall trend of increase
in serum cholesterol, triglyceride, and LDL-C levels by
increasing age (Table 3).
The standardized prevalence of dyslipidemia in differ-
ent gender and age subcategories are shown in Table 3.
The overall prevalence of undiagnosed dyslipidemia was
68.9 % and of diagnosed dyslipidemia was 12.5 %.
Among subjects with dyslipidemia the prevalence of un-
diagnosed dyslipidemia was 16.8 % and of diagnosed
dyslipidemia was 13.2 % that both types were more
prevalent in women. The prevalence of undiagnosed
Table 2 The standardized prevalence of abnormal lipid profiles; Cholesterol, Triglyceride, LDL and HDL, Community-Based Cohort
Study (KERCADR – 1st Round - N = 5558)
Cholesterol Triglyceride LDL-C HDL-C
Borderline High Borderline High Borderline High Borderline Low
Total 20.9 [19.5,22.2] 8.7 [8.0,9.6] 13.8 [12.6,14.9] 14.1 [13.0,15.2] 21.8 [20.4,23.3] 10.4 [9.6,11.4] 20.3 [18.8,21.9] 77.4 [75.7, 79.0]
Sex
Male 20.7 [18.8,22.7] 7.8 [6.7,9.1] 15.9 [14.2,17.9] 16.7 [14.9,18.6] 20.6 [18.7,22.7] 9.8 [8.5,11.3] 29.6 [27.0,32.3] 69.6 [66.9,72.2]
Female 21 [19.2,22.9] 9.6 [8.6,10.7] 12 [10.6,13.5] 12.1 [10.8,13.4] 22.9 [20.9,25.0] 11.1 [10.0,12.3] 12.2 [10.7,13.9] 84.2 [82.3,86.0]
Age groups
15–24 9.5 [7.4,12.2] 1.8 [1.1,3.2] 7.8 [5.9,10.2] 6 [4.4,8.3] 12.5 [10.0,15.4] 2.6 [1.6,4.0] 23 [19.7,26.7] 74.9 [71.1,78.4]
25–34 22.5 [19.6,25.6] 6.2 [4.6,8.2] 12.8 [10.6,15.3] 12.2 [10.0,14.7] 22.1 [19.3,25.2] 8.8 [6.9,11.0] 18.9 [16.3,21.8] 78.9 [75.8,81.7]
35–44 28.8 [25.8,32.0] 12.7 [10.5,15.3] 18.5 [16.0,21.4] 18.9 [16.3,21.8] 29.6 [26.4,32.9] 15.9 [13.4,18.7] 17.8 [15.3,20.6] 79.7 [76.7,82.4]
45–54 33 [30.1,36.1] 18.8 [16.4,21.5] 20.4 [17.9,23.2] 26.7 [23.9,29.6] 33 [30.0,36.2] 20.1 [17.5,22.9] 17 [14.6,19.6] 80.6 [77.8,83.1]
55–64 30.9 [27.8,34.3] 22.2 [19.4,25.2] 22.3 [19.5,25.3] 26.8 [23.8,29.9] 28.6 [25.6,31.9] 23.2 [20.4,26.3] 21.3 [18.5,24.4] 76.4 [73.2,79.3]
65–75 30.2 [25.9,34.8] 20.5 [17.0,24.6] 22.2 [18.5,26.3] 22.7 [19.0,26.9] 29.6 [25.3,34.2] 22.4 [18.7,26.6] 23.5 [19.5,27.9] 72.9 [68.3,77.1]
TC total cholesterol, HDL-C high density cholesterol, LDL-C low density cholesterol, TG triglyceride
Table 1 Lipid profiles categories based on the current measurements, history of diagnosis and taking drugs
Lipid profile
categories
Average of at the
time of recruitment
(TC)
Average of at the time
of recruitment (HDL-C)
Average of at the time
of recruitment (LDL-C)
Average of at the
















200–239 40–59 (men) 130–159 150–199 Negative Negative
50–59 (women)
Undiagnosed ≥240 <40 men 160–189 high 200–499 high Negative Negative
High-risk/very high-risk
serum concentration
<50 women ≥190 very high ≥500 very high






TC total cholesterol, HDL-C high density cholesterol, LDL-C low density cholesterol, TG triglyceride
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dyslipidemia was significantly higher in educated indi-
viduals than in those with lower educational level. Also,
smokers had higher prevalence of undiagnosed dyslip-
idemia than non-smokers. Similarly, opium users had
higher prevalence of undiagnosed dyslipidemia compared
with non-users. In addition, diagnosed dyslipidemia was
more prevalent in depressed than in non-depressed sub-
jects and also in anxious than in non-anxious persons.
Table 3 The standardized prevalence of dyslipidemia (undiagnosed and diagnosed lipid profiles), Community-Based Cohort Study
(KERCADR – 1st Round - N = 5558)
Subgroups N Normal Undiagnosed dyslipidemia Dignosed Dyslipidemia
Overall 5558 18.6 [17.1,20.2] 68.9 [67.2,70.6] 12.5 [11.6,13.3]
Sex
Men 2501 24.7 [22.2,27.3] 64.6 [61.9,67.2] 10.7 [9.5,12.1]
Women 3057 12.3 [10.6,14.2] 73.4 [71.4,75.4] 14.3 [13.2,15.4]
Age groups
15–24 806 23.6 [20.2,27.4] 75 [71.2,78.5] 1.4 [0.7,2.6]
25–34 1061 17.4 [14.8,20.3] 75.3 [72.0,78.3] 7.3 [5.6,9.5]
35–44 1037 14.5 [12.2,17.1] 69.3 [66.0,72.5] 16.2 [13.8,18.9]
45–54 1168 11.9 [9.9,14.3] 56.6 [53.3,59.8] 31.5 [28.6,34.6]
55–64 967 12.2 [10.0,14.7] 47.8 [44.2,51.3] 40.1 [36.7,43.6]
65–75 519 15.3 [11.9,19.4] 49.3 [44.4,54.3] 35.4 [30.9,40.1]
Education
Illiterate 772 20.7 [10.7,36.2] 59.8 [48.1,70.5] 19.5 [10.0,34.6]
Primary to high school 3734 19.1 [17.3,21.0] 68.9 [66.8,70.8] 12.1 [11.1,13.1]
Above high school 1052 16.6 [13.8,19.8] 69.5 [66.0,72.7] 14 [12.1,16.1]
Current cigarette smoker
No 4937 18.7 [17.1,20.4] 68.4 [66.6,70.2] 12.9 [12.0,13.9]
Yes 621 13.3 [8.9,19.4] 73.3 [65.1,80.1] 13.4 [8.7,20.1]
Opium consumption
No 4762 18.7 [17.1,20.4] 68.5 [66.7,70.2] 12.8 [11.9,13.8]
Occasional user 459 12.9 [8.5,19.1] 74.9 [69.0,80.0] 12.1 [10.1,14.4]
Depended user 337 28.4 [22.2,35.6] 60.6 [53.0,67.7] 11 [7.9,15.1]
Depression
No 3394 19.5[17.7,21.6] 68.9 [66.8,70.9] 11.6 [10.6,12.7]
Yes 2164 16.9[14.3,19.9] 70.4 [67.3,73.3] 12.7 [11.4,14.1]
Anxiety
No 1226 18.8 [15.6,22.5] 71.4 [67.6,74.9] 9.8 [8.2,11.6]
Yes 4332 18.7 [17.0,20.6] 68.2 [66.2,70.1] 13.1[12.1,14.1]
Obesity
Normal 2533 23.7 [21.6,25.9] 68.1 [65.7,70.3] 8.3 [7.3,9.4]
Overweight 2021 10.2 [8.0,12.9] 73 [69.9,76.0] 16.8 [14.6,19.1]
Obese 1004 8.4 [5.7,12.1] 74.6 [70.2,78.6] 17 [14.2,20.3]
Physical activity
Low 2456 17.3 [14.8,20.1] 68.7 [65.9,71.5] 14 [12.5,15.5]
Moderate 2612 18.3 [16.2,20.7] 69.6 [67.2,72.0] 12 [10.9,13.3]
High 490 23.2 [18.6,28.6] 68.9 [63.2,74.1] 7.9 [5.7,10.7]
Family History of dyslipidemia
No 2807 19.5 [17.4,21.7] 70.2 [67.8,72.4] 10.4 [9.3,11.5]
Yes 2751 17.6 [15.2,20.2] 67.9 [65.1,70.5] 14.6 [13.3,16.0]
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Meanwhile, overweight and obese cases had higher un-
diagnosed and diagnosed dyslipidemia compared to those
with normal weight. The prevalence of diagnosed dyslipid-
emia was significantly lower among subjects with high
physical activity (7.9 %: 95 % CI, 5.7–10.7 %) than those
with low physical activity (14 %: 95 % CI, 12.5–15.5 %).
Also, those with positive family history of dyslipidemia
suffered more from this lipid abnormality. By adjusting
baseline indicators as probable confounders (Table 4),
advanced age, anxiety, obesity, and family history of dys-
lipidemia could effectively predict dyslipidemia in study
population. In this context, gender, education level, smok-
ing, opium use and depression states were not found as
significant determinants of dyslipidemia. As shown in
Fig. 1, the prevalence of dyslipidemia in men increased by
fifth decade and then reduced by increase of age, while in
women it continued its rising trend by age. The peak age
of obesity in men was in the range of 55 to 59 years and in
women in the range of 45 to 49 years. Similarly, the peak
age of low physical activity in men was in the range of 55
to 59 years and in women in the range of 45 to 49 years
(Fig. 2).
Discussion
The present study aimed to determine prevalence of
dyslipidemia based on demographic characteristics as
well as medical status of general population and then as-
sesses main correlates of dyslipidemia and its association
with other CAD risk factors. In this regard, the overall
prevalence of undiagnosed dyslipidemia was 16.8 % and
of diagnosed dyslipidemia was 13.2 % that was signifi-
cantly influenced by advanced age, anxiety, obesity, and
family history of dyslipidemia, but not by smoking, edu-
cation level, opium addiction and depression state. Also,
we found a borderline level of cholesterol in 20.9 % and
excess level of cholesterol in 8.7 %. These borderline in-
dividuals are in risk of being hypercholesterolemic in
next few years as this phenomenon was found to in-
crease by advance age. On the other hand the prevalence
of undiagnosed dyslipidemia was more than diagnosed
dyslipidemia. These statistics show challenge in health
education, screening and controlling lipid profile in the
population under the study. In agreement with present
data a survey in Pakistan revealed that a large propor-
tion of the population had lipid abnormalities and fe-
males had significantly greater values of total cholesterol
[14]. Study on Jordanian adults showed that almost half
of the participants (48.8 %) had elevated serum total
cholesterol, 40.7 % had elevated LDL-C, 40.1 % had low
HDL-C, and 43.6 % had elevated triglyceride concentra-
tions [15]. In study by Sharifi and colleagues which per-
formed in Zanjan province of Iran, increased total
cholesterol (>200 mg/dL) was observed in 35.4 % of the
subjects. Except for the hypertriglyceridemia/low HDL-C
pattern, which was more common in males, the other
abnormal lipid profiles were more common in females
[16]. Tabatabaei and her colleagues reviewed and ex-
tracted published papers on prevalence of dyslipidemia
Table 4 Crude and adjusted odds ratio for different predictors
of dyslipidemia, Community-Based Cohort Study (KERCADRS –
1st Round - N = (5558)
Subgroups Crude OR Adjusted OR
Sex
Men — —
Women 2.4 [2.05,2.9] 2 [1.6,2.5]
Age groups
15–24 — —
25–34 1.4 [1.1,1.9] 1.1 [0.8,1.5]
35–44 1.8 [1.3,2.4] 1.1 [0.8,1.5]
45–54 2.2 [1.7,3] 1.3 [1,1.9]
55–64 2.2 [1.6,3] 1.6 [1.1,2.3]
65–75 1.7 [1.2,2.4] 1.2 [0.8,1.8]
Education
Illiterate — —
Primary to high school 0.7 [0.5,1] 1 [0.7,1.5]
Above high school 0.7 [0.5,1] 1 [0.7,1.6]
Current cigarette smoker
No — —
Yes 0.75 [0.59,0.96] 1.1 [0.8,1.5]
Opium consumption
No — —
Occasional user 0.9 [0.6,1.4] 1 [0.7,1.6]
Depended user 0.8 [0.6,1.1] 1.1 [0.7,1.5]
Depression
No — —
Yes 1.4 [1.1,1.6] 1.1 [0.9,1.4]
Anxiety
No — —
Yes 1.2 [1,1.5] 1 [0.8,1.2]
Obesity
Normal — —
Overweight 2.5 [2.1,3.1] 2.3 [1.8,2.9]
Obese 3.3 [2.5,4.4] 2.4 [1.8,3.3]
Physical activity
High — —
Moderate 1.7 [1.3,2.2] 1 [0.7,1.3]
Low 2.2 [1.6,2.8] 1.4 [1,1.9]
Family History of dyslipidemia
No — —
Yes 1.2 [1,1.5] 1 [0.8,1.2]
OR odds ratio, Numbers are reported as OR and [95 % Confidence Interval]
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in Iranian and international journals until September
2011. They found that hypercholesterolemia; high LDL-C
and low HDL-C were more prevalent in women, whereas
hypertriglyceridemia was more prevalent in men [17].
Also Esteghamati found that the prevalence of hypertri-
glyceridemia and hypercholesterolemia was 36.4 and
42.9 % respectively in the studied Iranian population and
hypercholesterolemia was higher among females and
hypertriglyceridemia among males [18]. None of the above
studies included considered mental health status as CAD
risk factor. The similarity of findings of last three studies
with findings of the present study implies that inappropri-
ate effectiveness of our health care system is at the na-
tional level.
Another fact was that the peak of prevalence of hyper-
lipidemia in women was ten years earlier relative to men
and this is associated with 10 year earlier peak in low
physical activity prevalence (Fig. 2) rendering those sus-
ceptible to cardiovascular events. There was more lipid
disorder in physically inactive individuals. Also many
Fig. 1 Prevalence of dyslipidemia and overweight/obesity by age group and sex in Kerman, 2011; (Community-Based Cohort Study
(KERCADRS – 1st Round - N = 5558)
Fig. 2 Prevalence of dyslipidemia and Low physical activity (Low PA) by age group and sex in Kerman, 2011; (Community-Based Cohort Study
(KERCADRS – 1st Round - N = 5558)
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more obese individuals had undiagnosed dyslipidemia
(42 %) and were unaware of it. It is noteworthy that
women who were physically inactive and older were
more dyslipidemic. The founding that anxiety is a deter-
minant of dyslipidemia along with high prevalence of se-
vere anxiety in our study population (29.1 % in females
and 16.7 % in males [11]) is another caution for our
health system menageries. These make the conditions
more cautious when considering high prevalence of low
physical activity of 39.2 % in men and 45.1 % in women
[11]. These facts along with more prevalence of undiag-
nosed dyslipidemia in our study population means that
we must reconsider screening program to detect this po-
tentially reversible and major coronary disease risk fac-
tor. In this regard as pointed by Ghayour-Mobarhan [19]
and others [20] performing appropriate programs for
screening and early diagnosing dyslipidemia followed by
proper medications resulted in appropriate control of
this abnormality. Ghayour-Mobarhan showed that trigly-
ceride, total cholesterol and low density lipoprotein
cholesterol were reduced by 27, 20.5 and 22.7 %, respect-
ively and high density lipoprotein cholesterol rose by
8.96 % among 238 hyperlipidemic individuals during one
year of attending lipid clinic [19].
Our data point to high prevalence of the other coron-
ary disease risk factors associated with dyslipidemia such
as low physical activity (LPA), obesity, anxiety and smok-
ing in dyslipidemic individuals either presented in the
current study or reported elsewhere [21, 22]. The posi-
tive association between dyslipidemia and LPA observed
in the present study (Table 4) has also been shown be-
tween LPA with hypertension and opium use [23, 24].
Opium causes reduction of plasma HDL cholesterol and
increases the risk of hypertension [25].Therefore our
local health program must consider these CAD risk fac-
tors in order to decrease CAD burden.
We acknowledge the limitation of our study as a
cross-sectional survey. Beside, this study benefited from
a relative large sample size, random sampling, and high
response rate and included new risk factors such as
mental health and opium consumption. For further stud-
ies, we recommend monitoring the lipid profile by a lon-
gitudinal prospective cohort study. Also it is required to
assess the efficacy of local and national intervention pro-
grams in managing and control of dyslipidemia.
Conclusion
In conclusion the results showed overall prevalence of un-
diagnosed dyslipidemia 16.8 % and of diagnosed dyslipid-
emia 13.2 % that was significantly influenced by advanced
age, anxiety, obesity, and family history of dyslipidemia.
Women are more at risk, although the prevalence of dys-
lipidemia especially borderline dyslipidemia was high in
both sexes and needs urgent actions due to mostly young
population of the country approaching middle ages in
near future.
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